ADiTx Therapeutics Inc.

2.94+0.0400+1.38%Vol 335.21K1Y Perf -41.90%
Jun 14th, 2021 16:00 DELAYED
BID2.93 ASK3.10
Open2.94 Previous Close2.90
Pre-Market- After-Market-
 - -  - -%
Target Price
14.00 
Analyst Rating
— — 0.00
Potential %
376.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap- 
Earnings Rating
Price Range Ratio 52W %
16.58 
Earnings Date
-

Today's Price Range

2.923.09

52W Range

1.629.58

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.16%
1 Month
27.83%
3 Months
-21.39%
6 Months
44.83%
1 Year
-41.90%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADTX2.940.04001.38
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume335.21K
Shares Outstanding0
Trades Count1.54K
Dollar Volume2.07M
Avg. Volume2.08M
Avg. Weekly Volume119.38K
Avg. Monthly Volume169.50K
Avg. Quarterly Volume287.39K

ADiTx Therapeutics Inc. (NASDAQ: ADTX) stock closed at 2.94 per share at the end of the most recent trading day (a 1.38% change compared to the prior day closing price) with a volume of 335.61K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. ADiTx Therapeutics Inc. CEO is Amro A. Albanna.

The one-year performance of ADiTx Therapeutics Inc. stock is -41.9%, while year-to-date (YTD) performance is 41.35%. ADTX stock has a five-year performance of %. Its 52-week range is between 1.62 and 9.58, which gives ADTX stock a 52-week price range ratio of 16.58%

ADiTx Therapeutics Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 3.71, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -157.37%, a ROC of -159.72% and a ROE of -365.54%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ADiTx Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ADiTx Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ADiTx Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ADiTx Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADiTx Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADiTx Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.19, ATR14 : 0.18, CCI20 : 90.03, Chaikin Money Flow : -0.08, MACD : 0.08, Money Flow Index : 77.98, ROC : 9.70, RSI : 59.51, STOCH (14,3) : 80.26, STOCH RSI : 1.00, UO : 43.37, Williams %R : -19.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADiTx Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ADiTx Therapeutics Inc.

ADiTx Therapeutics Inc is a pre-clinical stage, life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

CEO: Amro A. Albanna

Telephone: +1 909 488-0844

Address: 11161 Anderson Street, Loma Linda 92354, CA, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

67%33%

Bearish Bullish

70%30%

News

Stocktwits